Moody Aldrich Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Moody Aldrich Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.9M	Buy	28,160 +13,485	+92%	+$3.18M	1.6%	5
2026 Q1	$2.93M	Sell	14,675 -4,906	-25%	-$971K	0.53%	90
2025 Q4	$3.7M	Sell	19,581 -6,303	-24%	-$1.21M	0.69%	66
2025 Q3	$4.59M	Buy	+25,884	New	+$3.85M	0.87%	48
2019 Q3	–	Sell	-26,692	Closed	-$1.9M	–	134
2019 Q2	$1.9M	Buy	26,692 +1,054	+4%	+$77.6K	0.49%	77
2019 Q1	$2.01M	Sell	25,638 -11,946	-32%	-$905K	0.56%	69
2018 Q4	$3.18M	Buy	37,584 +4,128	+12%	+$440K	1.04%	42
2018 Q3	$5.73M	Sell	33,456 -8,914	-21%	-$1.34M	1.65%	15
2018 Q2	$5.48M	Buy	+42,370	New	+$4.73M	1.95%	10

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moody Aldrich Partners's LGND Position: Q2 2026 in Review

Moody Aldrich Partners increased its Ligand Pharmaceuticals (LGND) stake by 92% in Q2 2026, buying an estimated $3.18M and bringing the position to 28,160 shares worth $8.9M. The position accounts for 1.6% of the portfolio, ranked #5.

Moody Aldrich Partners first reported a position in LGND in Q2 2018 and has held it in 9 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Moody Aldrich Partners held 28,160 shares of Ligand Pharmaceuticals worth $8.9M as of Q2 2026.
Moody Aldrich Partners bought 13,485 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.18M.
Ligand Pharmaceuticals made up 1.6% of Moody Aldrich Partners's portfolio in Q2 2026, its #5 holding.
Moody Aldrich Partners first reported a position in Ligand Pharmaceuticals in Q2 2018 and has held it in 9 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.